Profile data is unavailable for this security.
About the company
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.
- Revenue in USD (TTM)0.00
- Net income in USD57.92m
- Incorporated2024
- Employees17.00
- LocationTevogen Bio Holdings Inc15 Independence Boulevard, Suite 410WARREN 07059United StatesUSA
- Phone+1 (646) 807-8832
- Fax+1 (302) 655-5049
- Websitehttps://tevogen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sagimet Biosciences Inc | 2.00m | -29.25m | 191.24m | 10.00 | -- | 1.03 | -- | 95.62 | -1.18 | -1.18 | 0.078 | 5.74 | 0.019 | -- | -- | 200,000.00 | -27.79 | -- | -29.32 | -- | -- | -- | -1,462.55 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -64.86m | 196.46m | 51.00 | -- | 0.8053 | -- | -- | -1.11 | -1.11 | 0.00 | 4.06 | 0.00 | -- | -- | 0.00 | -27.82 | -- | -29.32 | -- | -- | -- | -- | -- | -- | -- | 0.1075 | -- | -- | -- | -22.20 | -- | -- | -- |
| Gossamer Bio Inc | 105.32m | -71.65m | 198.83m | 135.00 | -- | 3.68 | -- | 1.89 | -0.3283 | -0.3283 | 0.4595 | 0.2389 | 0.3014 | -- | -- | 780,162.90 | -20.51 | -57.43 | -23.67 | -64.38 | -- | -- | -68.03 | -- | -- | -6.84 | 0.7847 | -- | -- | -- | 21.61 | -- | -- | -- |
| Instil Bio Inc | 0.00 | -119.58m | 200.58m | 49.00 | -- | 1.03 | -- | -- | -18.39 | -18.39 | 0.00 | 29.98 | 0.00 | -- | -- | 0.00 | -34.04 | -- | -35.48 | -- | -- | -- | -- | -- | -- | -- | 0.2958 | -- | -- | -- | 30.06 | -- | -- | -- |
| Adaptimmune Therapeutics PLC - ADR | 141.46m | -72.50m | 203.80m | 449.00 | -- | 2.12 | -- | 1.44 | -0.3452 | -0.3452 | 0.5922 | 0.3765 | 0.4256 | -- | 53.33 | 315,053.40 | -21.81 | -41.19 | -28.63 | -48.21 | -- | -- | -51.25 | -714.26 | -- | -- | 0.2058 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| CAMP4 Therapeutics Corp | 350.00k | -49.71m | 206.56m | 58.00 | -- | -- | -- | 590.17 | -2.55 | -2.55 | 0.0179 | 0.7707 | -- | -- | -- | 5,468.75 | -- | -- | -- | -- | -- | -- | -14,203.71 | -- | -- | -- | 0.0221 | -- | -- | -- | -11.54 | -- | -- | -- |
| TuHURA Biosciences Inc | 0.00 | -8.50m | 206.79m | 1.00 | -- | -- | -- | -- | -75.24 | -75.24 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -163.44 | -224.08 | -343.80 | -346.74 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.40 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | 57.92m | 208.19m | 17.00 | 3.25 | -- | -- | -- | 0.3758 | 0.3758 | 0.00 | -0.0452 | 0.00 | -- | -- | 0.00 | 1,217.57 | -- | -- | -- | -- | -- | -- | -- | -- | -702.58 | -- | -- | -- | -- | 99.69 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -19.37m | 208.86m | 13.00 | -- | 18.67 | -- | -- | -1.16 | -1.16 | 0.00 | 0.5789 | 0.00 | -- | -- | 0.00 | -97.93 | -- | -140.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Benitec Biopharma Inc | 0.00 | -22.37m | 209.64m | 16.00 | -- | 2.26 | -- | -- | -7.63 | -7.63 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -76.76 | -103.21 | -91.06 | -123.13 | -- | 152.10 | -- | -26,432.69 | -- | -- | 0.00 | -- | -100.00 | -- | -14.35 | -- | -15.35 | -- |
| Fulcrum Therapeutics Inc | 81.63m | -20.23m | 217.78m | 76.00 | -- | 0.7935 | -- | 2.67 | -0.3507 | -0.3507 | 1.31 | 4.40 | 0.2746 | -- | 29.13 | 1,074,079.00 | -6.81 | -50.55 | -7.14 | -55.91 | -- | -- | -24.79 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Tenaya Therapeutics Inc | 0.00 | -117.23m | 218.65m | 140.00 | -- | 1.94 | -- | -- | -1.44 | -1.44 | 0.00 | 1.42 | 0.00 | -- | -- | 0.00 | -70.20 | -- | -78.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Cabaletta Bio Inc | 0.00 | -89.98m | 219.33m | 136.00 | -- | 1.09 | -- | -- | -1.92 | -1.92 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -44.76 | -33.76 | -47.90 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -44.32m | 223.68m | 25.00 | -- | 3.72 | -- | -- | -0.4412 | -0.4412 | 0.00 | 0.7815 | 0.00 | -- | -- | 0.00 | -53.78 | -47.39 | -58.89 | -54.41 | -- | -- | -- | -- | -- | -- | 0.001 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Nkarta Inc | 0.00 | -107.91m | 225.08m | 150.00 | -- | 0.4967 | -- | -- | -2.01 | -2.01 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -21.95 | -32.39 | -23.07 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
Data as of Nov 08 2024. Currency figures normalised to Tevogen Bio Holdings Inc's reporting currency: US Dollar USD
3.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Polar Asset Management Partners, Inc.as of 30 Jun 2024 | 1.99m | 1.16% |
| Portland Global Advisors LLCas of 30 Jun 2024 | 1.91m | 1.12% |
| Harraden Circle Investments LLCas of 10 Jan 2024 | 838.97k | 0.49% |
| Cantor Fitzgerald & Co.as of 30 Jun 2024 | 650.00k | 0.38% |
| Geode Capital Management LLCas of 30 Jun 2024 | 340.80k | 0.20% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 208.30k | 0.12% |
| New York State Common Retirement Fundas of 30 Sep 2024 | 126.45k | 0.07% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 107.24k | 0.06% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 64.53k | 0.04% |
| Charles Schwab Investment Management, Inc.as of 30 Jun 2024 | 49.58k | 0.03% |
More ▼
Data from 30 Jun 2024 - 24 Oct 2024Source: FactSet Research Systems Inc.
